Efficacy study of sequential therapy with anthracycline, taxane, and eribulin in patients with HER2-negative locally advanced breast cancer (JBCRG-17)

Trial Profile

Efficacy study of sequential therapy with anthracycline, taxane, and eribulin in patients with HER2-negative locally advanced breast cancer (JBCRG-17)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2016

At a glance

  • Drugs Anthracyclines (Primary) ; Eribulin (Primary) ; Taxanes (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Jun 2016 Status changed from recruiting to active, no longer recruiting.
    • 07 Jun 2016 Interim results (n=26) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 22 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top